KeyBanc Initiates Becton, Dickinson And Co. With Bullish Stance

Becton Dickinson and Co BDX was initiated with a top-notch rating by KeyBanc Capital Markets Thursday. 

The Analyst

KeyBanc analyst Matthew Mishan initiated coverage on Becton Dickinson with an Overweight and $260 price target.

The Thesis

"We believe [the company] is positioned to win long-term, as it is playing an integral role in global health care systems leveraging its scale in developed and emerging markets to provide increasing value to customers over time," Mishan said in a note. (See the analyst's track record here.) 

Mishan sees the acquisition of C R Bard Inc BCR as an opportunity to increase Becton Dickinson's scope, adding more clinically complex medical devices and a defined channel into the homecare segment. 

CR Bard's 5-7-percent organic revenue growth profile is accretive to Becton Dickinson's 4-5-percent growth, the analyst said. The momentum is sustainable, given a pipeline of new product, indications and market opportunities — and potential revenue synergies, he said. 

"The combined entity generates sufficient FCF [initially $3B annualized] to delever over the next 3 years, while still comfortably growing its dividend." 

KeyBanc's earnings per share estimates for the combined company are: $10.77 in 2018, $12.49 in 2019 and $13.71 in 2020.

The Price Action

Becton Dickinson shares have gained about 34 percent over the past year.

Related Links:

Benzinga's Weekend M&A Chatter

Becton Dickinson Shares Favorably Valued As It Works To Boost Earnings

Photo courtesy of Becton, Dickinson And Co. 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorHealth CarePrice TargetInitiationAnalyst RatingsGeneralhomecareKeyBanc Capital MarketsMatthew Mishanmedical devices
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!